m. commercial-scale drug product fill facility, Liquid and lyophilization annual fill capacity of 10 million doses, Site utilizes flexible isolator-based and state-of-the-art Optima filling system that includes associated vial washer, depyrogenation tunnel, stoppering and capping units, automated loading/unloading system and 2 x 23 sq. Neurodegenerative and neuroinflammatory diseases, Pharmaceutical for cardiology, injection for joint diseases, smoking cessation, Contract drug discovery & development offering integrated solutions from Target ID through to Clinic, Targeting messenger RNA-modulating proteins, Highly selective peptide blockers for ion channels, Inhibitors against respiratory viral infections, Small Molecules to Treat Photoreceptor Mutations, Small molecule MKK4 inhibitors to treat acute and chronic liver diseases, Therapeutics and diagnostics for neurodegenerative diseases, Small Molecules, Biologics, Devices, Diagnostics, Novel therapeutics for the treatment of cerebrovascular diseases, Pharmaceutical manufacturing for hospital market, private market, and renal care, Small molecule kinase inhibitors for various diseases, Synthetic compounds targeting heat-shock protein, Nutrition, Diagnostics, Devices, Animal Health, Cell Therapy via ex-Vivo Small Molecule Treatment, Small Molecule Immunotherapy for Solid Cancers, Lipid emulsion product that is used to treat various non-opioid drug overdoses, Therapies and diagnostic tests for neurological disorders, Multifactorial treatment of antibiotic-resistant acne, Ophthalmic, respiratory, otolaryngologic, and wound care products, Integrated computational chemistry and artificial intelligence models to identify novel small molecules, Biologics, small molecules, plasma products, Treatments for neurodegenerative and neurodevelopmental disorders, Therapies for Genomically-defined cancers, Novel molecular and cellular mechanisms that regulate tumor development and metastasis, Combination or improved versions of approved products, Orally-administered, small molecule drugs for the treatment of inflammatory and gastrointestinal diseases, including cancer, Small Molecules for Cancers & Infectious disease, Biologics, Small Molecules, Cellular Therapy, Ophthalmology products (drugs, medical devices, and food supplements), contract development/manufacturing, Hyaluronic Acid-based pharmaceuticals, surgical aids, endotoxin-detecting reagents, Repositioning preclinical/clinical assets, Small Molecule, peptides, antibody therapies, contract analytical, Small Molecules, Biosimilars, Monoclonal Antibodies, Specialty, Generics, Consumer Products, Contract Manufacturing, Diagnostics, APIs, Small Molecules, Biosimilars, Licensing Western products to sell in Asia, Small Molecules & Diagnostic Manufacturing, ADC (Antibody-Drug Conjugate), Anti-biotics, Anti-coagulants & Anti-cancer therapeutics, Small Molecules, Stem Cell-based Biologics, Formulation, Drugs targeting disease-specific GPCR heterodimers. m. facility will be one of the largest CDMO facilities in northern China, New biologics center will house development laboratories and a biologics commercial-scale drug substance manufacturing facility with initial bioreactor capacity of 48,000 L, Invested $60 Million to provide facilities for early stage bioprocess development and clinical-scale GMP manufacture, Over 45,000 sq. WuXi Biologics, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, is investing €325 million in a new biopharmaceuticals contract manufacturing facility in Dundalk, Co. Louth. You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. m. (1.3 million sq. ft. global innovation site to be operational in 2021, New state-of-the-art facilities providing discovery, development, analytical development and QC testing and pilot and clinical-scale GMP manufacturing capabilities in one location. over 600 products in 13 areas, Small Molecules targeting cancer stem cells, Ophthalmology Small Molecules, Gene Therapies, Novel medicines that target the cGAS-STING pathway, Immunotherapy to Fight Infections and Inflammation, Dermatological Consumer Products and Drugs, In-licensing, marketing to Africa, Middle East, Pioneering Tunable Small-Molecule Degradation Platform, Small molecule for acute respiratory distress syndrome, Repurposing antimicrobial molecules to trump resistance, Small molecule inhibitors of RNA-modifying enzymes for the treatment of cancer, Fragment and structure-based small molecule drug discovery, Small Molecules Targeting Protein Mis-Folding, Treatments for neuronal Excitability Disorders, Crowdfunding to research existing therapies, Small molecules for inflammatory eye diseases and chronic pain, Oral and intranasal orexin receptor agonists using structure-based drug design approaches, Small molecules for respiratory indications, Modulating ERAP1 and ERAP2 in immuno-oncology, Next-gen ACE inhibitors, computer-aided drug design, Specialty pharmaceuticals, women's health, Innovative therapies and delivery methods, Proprietary charge-stabilized nanostructure (CSN) technology, Small molecular weight enzyme inhibitors; imaging and drug delivery. ResumeMatch - Sample Resume, Resume Template, Resume Example, Resume Builder,Resume linkedin,Resume Grade,File Convert. Small molecule drugs that target functional 3D RNA structures to treat human diseases. Drugs, Diagnostics, Veterinary medicine, etc. m. Drug Substance(DS) facility acquired from Bayer in December 2020, Two cell culture suites with 3 x 1000L perfusion and 6 x 2000L fed-batch bioreactor capacity and independent downstream area with pre- and post-viral filtration purification suites, 38 km （30 minutes driving） from the WuXi Biologics Drug Product facility in Leverkusen (DP7, another facility acquired from Bayer) - both sites will support WuXi Biologics’ Global Dual Source supply chain network strategy, Flexible and open spaces available for future expansion, Site ground breaking in June 2020 for 107,000 sq. By clicking “accept all”, you provide your specific and active consent for the use of last-mentioned categories of cookies. Are you willing to proceed? Please keep it in mind the protection of your privacy. Drug substance capacities: 2 x 2,000L and expandable to 4 x 2,000L, Liquid or lyophilized drug product fills into vials and pre-filled syringes at 10 million units/year and 1 x 10m2 lyo capacity, Planned to open in 2023 this 314,000 sq. Strong engineering professional with an Honours Degree from Trinity College Dublin and a Higher Diploma focused in Computer Science from Dundalk Institute of Technology. To see a list of the cookies and their purpose, Email: Recruiting_Biologics@wuxibiologics.com. Membrane Protein Stabilization Technology, Small molecule for Meniere's disease and noise-induced tinnitus, AMP-activated protein kinase activator compounds, Small Molecules for Lipid-related Diseases, Small molecule for multi-resistant bacteria, Treatments for cancers, infections, autoimmune diseases and other life-threatening disorders, Drug delivery technology; small molecule for cancer, Macrocycles', which are between small and large molecules, Small molecule for cns/ophthalmic diseases, Small Molecule Inhibitors for NOTCH-driven Cancers, Small molecule cancer drugs that modulate protein degradation pathways, Compounds Targeting cGMP-Enzyme Regulation System, Treatments for neurobehavioral and neurocognitive disorders, Proprietary technology platform for the design and selection of GPCR-targeting compounds, Microbial derived immunotherapeutic products, Novel drugs for obesity and anti-aging cosmedicine products, Treatments for cancer and Asian prevalent diseases, Small Molecules, Reformulation, Antibody Drug, Diagnostics, Novel positive allosteric modulators of the metabotropic glutamate receptor subtype 4, Natural compounds to create synergy with known pharmaceuticals, Turkish pharmaceutical with >150 products in 17 areas and R&D, Pharmaceuticals manufacturing. m. facility, operational since 2018 available for GMP Production in H2 2021. Small Molecules, Purification Equipment, etc. m. Early and late-stage development laboratories and clinical and commercial-scale drug substance and drug product GMP manufacturing, First facility in China approved by the U.S. FDA and EMA for production of a commercial antibody therapeutic, Facility dedicated to the development, and GMP manufacture of drug substance and drug product of bioconjugation products (e.g., antibody drug conjugates), Over 10,100 sq. We use cookies that are necessary for our website to function properly. mPGES-1 inhibition in cardiovascular diseases and cancer. m. facility resides on 26-hectare site acquired in April 2018 and was supported by by the Irish Government through IDA Ireland, This“Factory of the Future” will provide biologics commercial-scale GMP manufacturing, Operations to commence in 2021 with additional expansion to include commercial-scale drug product manufacture by 2022, WuXi Vaccines will construct a purpose-built vaccine manufacturing facility adjacent to the WuXi Biologics “Factory of the Future.”, Over 13,000 sq. Drug delivery, biotherapeutics, and new small molecule discovery. All Rights Reserved. Small molecule for mouth/throat, dermatology, urology, gynecology, cardiology, metabolism, Small molecule for research and various disorders, Small Molecules for Psychiatry & Neurology, Small Molecules for RNA-mediated Diseases, Therapies for Central Nervous System Diseases, Medically-assisted detoxification from opioids, Small Molecules Targeting Prostate Cancer, Acquisition & Licensing of Small Molecules and Devices, Devices and therapeutics for preterm labor prevention, Small molecule for gi, neuro, anti-viral, and cancer, Drug delivery technology, small molecule for neurodegenerative disease, protection against radiation, diabetes, Small molecule for women's health, scar and wound care topicals/plasters, Pharma/dermo-cosmetics lab developing osteoarthritis and skincare products, Restoring neuronal function with drugs that specifically stimulate the neuronal microtubules, Drug discovery and repurposing for rare monogenic diseases, Therapeutic solutions for respiratory diseases, Develops small molecules drug candidates in infectious & metabolic diseases and oncology, Loading Red-Blood Cells with Therapeutics, Pharmacological therapeutic approach for the protection of organ transplants, Small molecule for treatment of lysosomal diseases or specific cancers, Therapies Targeting Cancer Stem Cell Proliferation, Epicutaneous immunotherapy for allergic desensitization, API manufacturing; Large scale continuous chromatography, Therapeutics harnessing the Integrated Stress Response, Drugs for pediatric neurological conditions, CDMO Services, Purification and Separation Equipment. Australia - North Perth: Novel, clinical-stage synthetic cannabinoid product pipeline for dermatology and antimicrobial indications 苏公网安备 32021102001100号. m. multi-facility site is home to one of the largest biologics development teams and laboratories in the world, One of the first sites in the world with an integrated platform spanning biologics drug discovery to late-phase (phase III) clinical development, 1.6 million sq. Directory of Small Molecule Pharmaceutical Companies. Activity Meet some of our employees working at our (WuXi Biologics) state-of-the-art biologics manufacturing facility in Dundalk… Over 45,000 sq. ft. facility, State-of-the-art single-use technology facility is located in the world’s top biotech hub, Site dedicated to biologics GMP clinical- and commercial-scale manufacturing, Facility focused on biologics development and drug substance GMP clinical-scale manufacturing, Over 66,000 sq. We also use cookies to retain user preferences, for analysing our website traffic and for statistical and web-traffic marketing purposes. Acquired site as well as its labor force from Pfizer China (“Pfizer”) in March 2021. Multiple facilities with a total area of 160,000 sq. of Biosafety Level 2 laboratories, Copyright © 2020 WuXi Biologics. ft. facility located in the robust biopharmaceutical tristate region of NY, NJ and PA, More than 33,000 sq.ft. m. facility resides on 26-hectare site acquired in April 2018 and was supported by by the Irish Government through IDA Ireland This“Factory of the Future” will provide biologics commercial-scale GMP manufacturing Operations to commence in 2021 with additional expansion to include commercial-scale drug product manufacture by 2022 learn more. Located mid-way between Dublin and Belfast, the facility is less than an hour’s drive from Ireland’s two largest cities. m. freeze dryers (lyophilizers), Multiple vial CCS sizes range from 2R to 50R, State-of-the-art 30,000 sq. Finally, China’s open-access biologics technology platform, WuXi Biologics, is hiring at its biopharma manufacturing facility in Dundalk, Co Louth. Monoclonal Antibodies, Small molecule drugs against cancer and autoimmune diseases, Modernizing Traditional Chinese Medicines, Treatments for autoimmune diseases and inflammation, Developing first-in-class therapies targeting key biological drivers of chronic inflammatory and fibrotic diseases, Biologics, Small Molecules, Therapeutic Antibodies, Small Molecules targeting cancer and liver diseases, Small Molecules Targeting Cancer and Autoimmune Diseases, Personalized immuno-therapeutic drugs for autoimmune diseases, Small Molecules for Musculoskeletal Diseases, Small molecules that activate progenitor cells, Bifunctional small molecules for protein degradation, Small Molecules for Neurology Indications, Sublingual thin film formulation, oral small molecule, Erectile Dysfunction Treatment that works for Diabetes and Metabolic Syndrome Patients, Small Molecules Modulating Tumor Microenvironment, Targeting essential protein-protein interactions required for error-free DNA damage repair, Small molecules for movement disorders (Parkinson's akinesia/dyskinesia), Small Molecules, Specializing in psychiatric/neuro, Small Molecule Discovery Using DNA-Encoded Chemical Libraries, Developing new proprietary drugs for treating all variants of hyperphenylalaninemia, diagnostics, Cancer Treatments with Companion Diagnostics, R&D/clinical trials treatment of chemotherapy resistance. WuXi Biologics. Multi drug-resistant bacterial infections. Dental pharmaceuticals (pain managements, endodontics & restorative, regeneration & surgery), Small molecule compounds that selectively target drug-resistant tumors, High-end radio-ligand diagnostics and therapeutics, Dietary related metabolic disease therapies, Small Molecules based on Omega-3 Fatty acid metabolites, R&D for small molecules to treat cns disorders, Lubricants, Catheter Inflation, Instillation Therapy, Small molecule for sore throat/respiratory, biological for well-being, small molecule for uti. China Chemical and Pharmaceutical Company, Novel, clinical-stage synthetic cannabinoid product pipeline for dermatology and antimicrobial indications, Small molecule for chronic inflammatory disorders, Small molecule treatments for neurological diseases along with a unique peripheral mitochondrial biomarker, Small molecule chemical chaperone intended to rescue folding of the Z variant of alpha-1-antitrypsin, Therapeutics & Diagnostics targeting nf-P2X7, Small molecules, diagnostics, traditional, Clinical-stage oncology company with a lead program in US-based phase II trials for brain cancer, Small molecule for neurological disorders, Small molecule/peptide for neurology, small molecule injectables for cancer, anesthetic, women's health, Antibodies and small molecules for treating tuberculosis, Peritoneal dialysis fluid including a cytoprotective compound, Cell imaging platform, small molecule for lung cancer, Dodecafluoropentane (DDFP)-based oxygen therapeutics, Non-opioid therapeutics that relieve chronic pain, Endocannabinoid system-based prescription drugs, Small Molecules for rare genetic diseases, Novel antibiotics, antifungals, and treatments for certain cancers and dermatological conditions, Radiopharmaceuticals based on linking single domain antibody fragments with radioisotopes to treat cancer, Small molecule for respiratory, cardiovascular, pain, dermatology, and vitamins, Mitochondria-targeting drug to burn calories, Small synthetic molecule replacement for antibody-based therapeutics, Treatments for diseases affecting the hypothalamic-pituitary-adrenal (HPA) axis, Inhibitors to a the soluble epoxide hydrolase, Novel class of compounds that target the extracellular matrix, Therapeutics targeting innate and adaptive immune systems, Small Molecule, Carbon Monoxide Monitoring Device, Small molecule for respiratory infections, In-licensing of clinical oncology products, Regenerative Medicine, Cell Therapy, Small Molecule, Treatment for movement disorders and falling, Targeting cancer cells that over-express certain unique amino acid transporters, Acquisition & Development of cancer therapies, Small Molecules for Neurodegenerative and other areas, Novel treatments for gastrointestinal diseases and disorders, First-in-class pharmaceutical discovery and development, Non-opioid analgesic and neurology specialty pharmaceutical company, Topical PI3K inhibitor treatments for Venal Malformations, Small molecules focused on GPCR targets for oncology indications, Deep Eutectic Ionic Liquids for Therapeutics, New applications for existing cosmetic dermatology product, Treatments for gout and chronic kidney diseases, Therapies for the treatment of Idiopathic Pulmonary Fibrosis, First-in-class, selective A3 adenosine receptor agonists, Small-molecule, targeted protein degraders, Galectin Blocking, Cancer & Organ Failure, Small Molecules for Neurodegenerative Indications, Novel central nervous system-targeted assets, Targeted Oncology Company; Small Molecules, License, develop, and commercialize product candidates, Small molecules for neurological conditions, Antiviral Drugs Development, Antiviral Assay Services, Therapeutics for metabolic and endocrine disorders, 3D tissue technology to discover and develop drugs, Small Molecules Targeting Signal Transduction, Therapies for hepatologic diseases and viral infections, Small molecule cancer drugs that stabilize the direct interaction of oncogenic proteins with the 14-3-3 class of adaptor proteins, Targeted medicines for neurodevelopmental disorders, Phenotypic screening to discover novel drugs for complex neurological and psychiatric diseases, Small Molecule Targeting Tyrosine Kinase Receptors, Discovery of treatments for undruggable proteins, Next-gen bifunctional small molecule drug discovery, Monoclonal Antibody & Small Molecule Targeting Infectious Diseases, Drugs targeting the fatty acid synthase enzyme, Small molecules for liver disease and cancer, Neurodegenerative therapies, BBB-crossing antibody, Small molecule compounds that act by unlocking protein-protein interfaces, Drug Discovery Using Chemoproteomics Platform, Therapeutics that alter gene expression patterns by targeting enzymes that regulate gene transcription, Assisting companies to advance drug candidates, Treatments for diseases of protein misfolding, including cataracts, Small molecules that drug traditionally undruggable targets, Reformulated, Topical Dermatology Products, Imaging Agents, Modified glucocorticoid to treat chronic pain, Small Molecules, Biologics, Antibody Therapy, Generics, Small Molecules. Small molecules that act upon human microbiome, Small Molecule Prodrugs of Known Entities, Female Sexual Interest/Arousal Disorder Treatments, Pre-clinical research for novel treatment of neurological/neuropsychiatric dopamine related disorders, Small molecules for multidrug resistant infection, Small molecule for acute kidney injury, diabetes, copd, pah, BBB drug delivery technology; small molecule for cancer, ms, Allosteric receptor modulators for a range of phosphatase targets, Facioscapulohumeral dystrophy diagnosis & treatment, Innovative drugs targeting genomic instability in cancer; Diagnostics, Ophthalmic and Injectable Specialty Pharmaceuticals; 505(b)(2), Specialty Small Molecules, Gastroenterological, Functional microtissues engineered from induced pluripotent stem cells to facilitate high-throughput, human-based drug discovery, Small molecule for gi; medical device for endoscopic procedures, Generics, Biologics Development, Small Molecules, Technologies to target and treat activated macrophages in the body, Heat-Activated Liposomal Technology, Oncology, Products to treat or prevent fibrotic and inflammatory diseases with high unmet medical needs, Improved specialty pharmaceuticals and treatments for new areas of use, Antibodies, Biologics, Small Molecule Therapies, Identifying drugs that modulate autophagy, Small molecule (oligosaccharide) for cystic fibrosis, chronic obstructive pulmonary disease, and chronic infections, Drugs for autoimmune/metabolic and neurological diseases, focus on individuals with down syndrome, Acquisition & Worldwide Commercialization, Small Molecules for Protein Misfolding diseases, Small molecules with copper chelating properties, Novel anti-inflammatory, first-in-class synthetic drugs, Small molecule inhibitors of mRNA translation initiation for treating cancer, Therapies for the treatment of metastatic cancers, Pulmonary disease and kinase inhibitor technology, Small molecules, peptides, diagnostic, vaccine, Small molecule targeting Innate Repair Receptor, Combination Therapy - Hypothermia Induction, Novel Therapeutics for Inflammatory and Vascular Diseases, Small molecule for circulatory/neurological disorders, Targeted Alpha Therapeutics for chemo-resistant Cancers, Acquisition, commercialization of various products, Screening compounds for gut microbiome impact, Acquisition & Marketing of Approved Products, Stimulating the body’s innate tissue repair and regeneration mechanisms with biologic and small molecule drugs, Therapeutics to combat vascular dysfunction to stabilize the body as it battles disease, Anti-nature Topical OTCs (Insects, Poison Ivy), Small Molecules for Cardiovascular Indications, Specialty Pharmaceuticals for Parkinson's, Small Molecules for stress, mood, behavior, Transdermal synthetic cannabinoid treatments, Antivirals targeting non-viral human proteins, Small molecules targeting oxygen metabolic pathways, Therapies derived from ubiquitin proteasome pathway, Acquisition & Development of Drug products, Targeting enteric nervous system of the gut, Small molecule for concentration disorders of the kidney, Oncology CRO with extensively characterized PDX models in over 15 cancer indications, first-in-class, gain-of-function small molecules, Genetic Disease Treatments Discovery Platform, Developing solutions for Cushing’s Syndrome, Type 1 and Type 2 diabetes, Small molecule for cancer/infectious disease; various serums/reagents, Novel therapeutics for neoplastic and inflammatory diseases, Small Molecules, Biologics, Protein Technologies, Novel inhibitors of ubiquitin-specific protease 15, DNA, polymer, small molecule combination Hepatitis B treatment, Small Molecules Assisting Regenerative Medicine, Transplantation, Identification and development of novel target ligands and new therapeutics, Biologicals and small molecules for cancer, Technology to develop therapeutics that render calcified tissue and organs supple again, Generic Respiratory Medications & Contract Manufacturing, R&D for pharma (neurodegenerative disease), cns diagnostics, Pharmaceuticals for various eye conditions, R&D too, Drug Discovery targeting intrinsically disordered proteins, Repurposing for Pediatric Cancer Treatments, New drugs based on the modulation of adenosine receptors, First-in-class causing autophagy molecules, Drug Discovery Engine to deliver pharmacological chaperones, Precision drugs targeting the tumor stroma; ADC, monoclonal, biologics, companion diagnostics, Pharmaceuticals for allergy and immunology, Biosimilars, Contract Manufacturing, Licensed Products, Orphan receptor drug discovery; small molecule for Alzheimer's, mGlur5 inhibitors for post-stroke treatment, Tumor selective mri agent; radionuclide cancer treatment, Small molecule for neurology, cardiology, and cancer, Pharmaceutical development focused on anti-psychotics, anti-depressant/anxiolytics, analgesics. Dundalk, Ireland. Protein Misfolding Correction - CNS, etc. ft.) multi-facility site will be the largest CDMO site in western China, New integrated manufacturing center will include drug research and development and commercial-scale drug substance manufacturing facilities with initial bioreactor capacity of 48,000 L, Planned 82,160 sq. 17,748 sq. Small Molecules for Dermatology Indications. 苏ICP备16033595号 Erythroid differentiation regulator 1 targeting therapies, Small Molecules, Vaccines, Biologics, Aesthetic Medicine, Plant-derived small molecules for oncology, Small molecule for neurological conditions, Chiral switching of existing therapies / candidates, Membrane Lipid Therapy, Synthetic Fatty Acids, Computational chemistry platform to develop small molecule therapeutics, Nucleoside and nucleotide analogs to inhibit the viral RNA polymerase, New medicines to protect, restore & repair hearing, Neurological and neuropsychiatric therapies, Small Molecules designed for Distinct Protein Domains, Novel, inhaled small-molecule pan-JAK inhibitor, CNS & Diabetic Neuropathic Pain Treatments, High-value targets validated by human genetics, Treatment of TBI, Stroke, and Alzheimer’s Disease, and other injuries to the brain, Small Molecules for neurodegenerative disorders, Discovery of novel treatments for neurodegeneration, cognition and rare diseases, Small Molecules for Undruggable Protein Targets, RNA sequencing for drug discovery, Antibody-drug conjugates, Small molecule targeting of beta-propeller domains, In-Licensing & Developing Oncology Assets for Sale, Company acquires rare disease products moves forward then spins out companies, Drugs to regulate hepcidin expression within the body, Drug discovery through genetic analysis of nature, Therapies targeting brown adipose fat tissue, Treatments for Disease-Causing Condensates, Unlocking gene control mechanisms to develop small molecule therapies, First-in-class therapies against historically intractable targets, Therapeutics to improve mitochondrial function, Drug discovery related to central metabolic signaling pathways, Small molecules that can modulate protein interactions found in disease states, Computational–experimental platform to discover lead drug candidates that regulate intrinsically disordered proteins implicated in cancers and neurodegenerative, Small Molecules, Vaccines, Biologics / Diagnostics, Structure-based Drug Design for Kinase Targeting, Small molecule therapies designed to reprogram RNA processing, Cancer drugs that target specific types of poly ADP-ribose polymerase, Gene Therapy, Devices, Biologics, Small Molecules all for DMD, Treatments for rare neuroendocrine tumors and rare endocrine diseases, Microglia-based Therapeutics for Neurodegenerative Diseases, Podocyte-targeting Kidney Disease Treatments, Discovering novel functions of existing molecules, Inhaled glycopolymer-based therapeutics for the treatment of pulmonary disease, Compounds based on complex carbohydrate chemistry, Compounds Designed for Microbiome Targets, Small molecule modulators of organelle specific chaperones, Oncolytic Viral Immunotherapies for Cancer, Therapies for prevalent, degenerative diseases as well as sustained-release drug delivery systems, Treatments for oxidative stress related diseases, Non-invasive therapeutic agents based on proprietary ketamine analogs, Small Molecules, Helminth worm eggs as a drug, Nocions which preferentially target activated sensory neurons that are responding to external insult, Small Molecules targeting proteins in the inflammasome and nucleic acid sensing signaling pathways, Ubiquitin-proteasome system based therapeutics, Small Molecules acting to degrade proteins, Molecular targets in oncology that are validated but difficult to drug, Functional and motility gastrointestinal disorders, Small Molecules with Companion Diagnostics, Custom Antibody Services, Monoclonal antibody, toxin conjugate, others, Small molecules for neuro / psychiatric disorders, Treatments for Duchenne muscular dystrophy and other severe genetic disorders, Drug development company with a focus on developing therapeutics for Duchenne muscular dystrophy, Group of Many Small Drug and Diagnostic Companies, Small Molecules, Biologically derived products, Small Molecules for Ophthalmic Indications, Topical therapies that condition damaged tissue and control microbial biofilms, Diagnostics & Therapeutics for Alzheimer's, Antibacterial Small Molecules, Vaccines for UTI, Diagnostic imaging and therapeutic agents for neurodegenerative diseases.
Les Pouvoirs Extraordinaires Du Corps Humain Youtube, Avis De Décès Nice Matin, The Roaring Twenties Summary, The Cider House Waupoos, Tu La Connais Ou Tu L'as Connais, Ladies Vs Gentlemen Flipkart Answers All Episodes, Blagues Novembre 2020,
Commentaires récents